Analyzing Karyopharm Therapeutics (NASDAQ:KPTI) & XTL Biopharmaceuticals (NASDAQ:XTLB)

XTL Biopharmaceuticals (NASDAQ:XTLB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Risk & Volatility

XTL Biopharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares XTL Biopharmaceuticals and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Institutional and Insider Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for XTL Biopharmaceuticals and Karyopharm Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
Karyopharm Therapeutics	1	2	3	1	2.57

Karyopharm Therapeutics has a consensus price target of $11.50, indicating a potential upside of 498.96%. Given Karyopharm Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than XTL Biopharmaceuticals.

Valuation and Earnings

This table compares XTL Biopharmaceuticals and Karyopharm Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	13.12	-$6.97 million	($0.64)	-4.19
Karyopharm Therapeutics	$146.07 million	0.30	-$196.04 million	($15.09)	-0.13

XTL Biopharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.